Retatrutide (Triple Agonist, Investigational)

Retatrutide, Eli Lilly's investigational triple GLP-1/GIP/glucagon receptor agonist, achieved a 30.3% average weight loss in the TRIUMPH-1 Phase 3 trial — the highest ever recorded in a randomized obesity trial. This outperforms #1 Zepbound's 20.9% and #2 Wegovy's 14.9% by engaging glucagon receptors to boost thermogenesis and fat oxidation. At 12 mg weekly over 96 weeks, participants lost approximately 70-71 pounds, with additional benefits including a 75.8% reduction in osteoarthritis pain and a 72% reversal rate of prediabetes. An NDA filing is expected in late 2026, with approval anticipated in 2027; no list price or commercial name is yet available.